Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Cordyceps (Cordyceps militaris / sinensis)

Plain-language summaryIntrigue 55 / 100

Cordyceps is a medicinal mushroom traditionally used for energy and athletic performance. The active compound cordycepin (3-deoxyadenosine) has been studied as an adenosine analog and possible antiviral. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

28/100

OTC mushroom with modest exercise signal; the interesting moiety is cordycepin, not the extract

Yeah, there’s something genuinely interesting buried in here — cordycepin (3′-deoxyadenosine) is a real adenosine analog with documented receptor activity and a modest preclinical anticancer signal — but cordyceps as a research object is not the way to get at it. If you want to study cordycepin’s adenosine receptor pharmacology or explore the nucleoside antitumor literature, you use isolated cordycepin, not a gram of mushroom extract with variable active compound content and a basket of unstandardized polysaccharides sitting alongside it.

The human evidence is real but modest. A handful of small RCTs have documented improvements in exercise tolerance and attenuated cardiovascular response to exertion — the Yi et al. data on VO2max, some follow-on work with standardized C. militaris extract — and that is genuinely more than a lot of adaptogens can claim. The problem is effect size. These are small-N studies, the magnitude of improvement is mild, and the mechanistic pathway connecting mushroom polysaccharides to better aerobic output is not well worked out. The adenosine story is plausible but, as the abstract acknowledges, incompletely characterized.

The differentiation picture is weak. Cordyceps sits in a crowded functional mushroom category alongside lion’s mane, reishi, ashwagandha, and several others with broadly similar human evidence profiles. It doesnt dominate any of those competitors on a meaningful axis. The endurance angle is probably the strongest niche, but even there the signal is not dramatic enough to make cordyceps a first-choice tool for exercise physiology research.

We don’t think the bench value is zero. Cordycepin itself is worth attention in an immunology or nucleoside-pharmacology context — it turns up in the adenosine analog literature in genuinely interesting ways, including antiproliferative work that is mechanistically distinct from standard cytotoxics. But as a whole-organism extract the utility for precision mechanistic work is limited. Standardization is inconsistent, the ratio of cordycepin to polysaccharides to ergosterol varies by source, and youre essentially working with a poorly defined mixture when the active moiety is accessible in purer form.

The OTC reality also matters. This is a product available at any supplement retailer, regulatory status is uncontrolled, and the literature base skews toward industry-adjacent work and traditional medicine scholarship rather than rigorous mechanistic investigation. Thats not disqualifying on its own, but its context for where cordyceps research has historically been prioritized. Interesting ethnobotanical history, real but limited modern evidence, and a more compelling research target in cordycepin that is accessible without the extract noise.

Novelty

16

Mechanism promise

24

In-category differentiation

28

Evidence quality

42

Translational signal

38

Research bench value

22

Rationale Cordyceps scores below the generic-nutrient cap on raw calculation — novelty is minimal for a widely-available OTC mushroom, mechanism is incompletely characterized, and the differentiation case in the adaptogen category is weak. Cordycepin has real adenosine-pharmacology interest but investigators wanting that signal would use isolated cordycepin, not a standardization-variable whole extract.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Medicinal mushroom / cordycepin source

A parasitic fungus traditionally used in Chinese medicine for fatigue and physical performance, characterized by cordycepin (3′-deoxyadenosine) bioactivity.

Abstract

Cordyceps (Cordyceps militaris and the related Cordyceps sinensis / Ophiocordyceps sinensis) are parasitic fungi traditionally used in Chinese medicine for energy, endurance, and respiratory function. The active constituents include cordycepin (3′-deoxyadenosine), polysaccharides, and ergosterol derivatives. Cordyceps militaris is now the predominant commercial form due to the rarity and protected status of wild C. sinensis. Modest cardiovascular effects (improved exercise tolerance, attenuated blood pressure response) have been documented in randomized trials. Mechanism is incompletely characterized; cordycepin has documented adenosine receptor effects and modest anticancer activity. Doses are typically 1 to 3 grams per day of mushroom extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-111Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylphenidate

Plain-language summaryIntrigue 80 / 100

Methylphenidate, sold as Ritalin and Concerta, is the most prescribed ADHD medication. It blocks dopamine and norepinephrine transporters but also produces some monoamine release. Schedule II in the US. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

48/100

The canonical DAT reuptake inhibitor, indispensable as a reference compound but not a frontier research target

Look, methylphenidate has been in the literature since 1944. Eight decades of data, thousands of trials, a mechanistic profile that most first-year pharmacology students could sketch from memory. That doesnt make it useless as a research tool. It does mean that the score here reflects research merit, not clinical validation.

The mechanism is clean and well-defined: competitive reuptake inhibition at DAT and NET, no meaningful transporter inversion unlike amphetamine-class compounds. The (R,R)-enantiomer, dexmethylphenidate, carries the bulk of pharmacological activity. This selectivity matters for probe work; if you’re trying to parse dopamine reuptake inhibition from active release in a catecholamine circuit, MPH vs. d-amphetamine is still a reasonable pairing for that experiment. Thats essentially where the bench value lives in 2026.

Evidence quality is unambiguous. FDA approval in 1955, decades of replicated phase 3 trials across pediatric and adult populations, extensive neuroimaging data from PET and fMRI paradigms, mature biomarker work. Translational signal is about as clean as you get in CNS pharmacology. If you need a DAT inhibitor with massive safety and PK characterization behind it, methylphenidate has it. We’re not questioning whether it works.

What we are questioning is whether this compound is interesting as a primary research target right now. The answer is mostly no. The mechanism isn’t new. The indication space is saturated. The interesting questions in ADHD neuropharmacology have shifted toward circuit-level characterization, non-stimulant mechanisms (viloxazine, guanfacine, atomoxetine’s NET selectivity in developmental populations), and the intersection of executive function with sleep and reward architecture. Methylphenidate is a useful comparator in those experiments, not the headline compound.

Where it retains genuine bench value is as the reference DAT reuptake inhibitor in mechanistic catecholamine studies. The releaser-versus-reuptake-inhibitor distinction is still a live question in abuse liability modeling, reinforcement learning paradigms, and dopamine clearance kinetics in striatal microdialysis work. Having an FDA-characterized compound with published PK across enantiomers and multiple extended-release formulations is useful if you’re running those comparisons. The literature depth alone makes it a credible control arm.

Schedule II scheduling is the operational reality here. Institutional DEA registration, controlled substance inventory, and the attendant paperwork are non-trivial costs for any lab. The calculated score sits well under the 65-point Schedule II ceiling, so the cap doesn’t bind, but the compliance overhead is worth naming for any group setting up a new MPH protocol.

Honestly, if you’re considering methylphenidate as a primary research target rather than a reference compound or pharmacological control, we’d ask what question you’re trying to answer that the existing literature hasn’t already addressed. The depth of that literature is both its greatest asset and the clearest argument for deprioritizing it as a frontier investigation target.

Novelty

20

Mechanism promise

28

In-category differentiation

38

Evidence quality

82

Translational signal

85

Research bench value

60

Rationale Methylphenidate scores high on evidence quality and translational signal but is severely penalized by near-zero novelty and a mechanism fully characterized for eight decades; its 2026 research value is as a pharmacological reference arm in dopaminergic studies, not as a primary investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenethylamine DAT/NET inhibitor

A phenethylamine-class DAT and NET inhibitor FDA-approved as Ritalin and Concerta for ADHD.

Abstract

Methylphenidate (Ritalin, Concerta; CAS 113-45-1; molecular formula C14H19NO2; molecular weight 233.31) is a phenethylamine-class psychostimulant first synthesized in 1944 and approved by the FDA in 1955. The compound is a primary clinical treatment for ADHD and is also used for narcolepsy. Mechanism is dopamine and norepinephrine transporter inhibition (DAT, NET); unlike amphetamine-class stimulants, methylphenidate does not produce significant monoamine release through transporter inversion. The (R,R)-enantiomer (dexmethylphenidate) carries most of the activity. Pharmacokinetics: plasma half-life 2 to 4 hours (immediate release); extended-release formulations span 8 to 12 hours. Schedule II in the United States.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-144Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
DHEA (Dehydroepiandrosterone)

Plain-language summaryIntrigue 60 / 100

DHEA is the most abundant circulating steroid hormone, produced by the adrenal glands. Levels decline with age. It serves as a precursor to both testosterone and estrogen. Sold as a supplement with mixed evidence for benefit in healthy adults. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Mature endogenous steroid with mixed clinical record and limited frontier research value

Look, DHEA is one of the most studied endogenous steroids on the planet, and thats kind of the problem. The literature is enormous, the compound has been an OTC supplement in the United States since the 1990s, and after thirty-plus years of serious clinical investigation the picture is underwhelming. Mixed results across virtually every indication: cognitive function in aging adults, depression, sexual function, bone density, body composition. The adrenal insufficiency angle is the most defensible, but even there the effect sizes are modest and the patient population is narrow enough that generalizability is a real concern.

The mechanism is more layered than most people credit. DHEA isn’t only an androgen/estrogen precursor. It’s also a sigma-1 receptor ligand and a positive allosteric modulator at NMDA receptors, which places it in the neurosteroid conversation alongside compounds like allopregnanolone and pregnenolone. That angle is genuine and underappreciated. But here’s the problem: if you’re running neurosteroid biology, you have cleaner probes. Sigma-1 work has more selective ligands. NMDA modulation has better characterized tools. DHEA does several things at once, none of them with the selectivity that makes a clean research question possible. The multi-target profile reads as messy rather than elegant.

The age-related decline narrative is compelling on its face. Circulating DHEAS peaks in the mid-20s and reaches 10 to 20 percent of that level by age 70. Thats a dramatic and highly reproducible fall. But replacement studies haven’t consistently reversed the endpoints that decline is supposed to explain. The working hypothesis now in serious aging research is that physiological DHEA decline may be partly a consequence of aging rather than a primary driver, and that systemic oral replacement doesn’t recapitulate the local paracrine production that matters at the tissue level. That reframe, if correct, makes the classic intervention paradigm less compelling.

Differentiation is another weak point. For hormone restoration in the clinic, direct testosterone or estrogen replacement is better characterized and clinically superior on relevant endpoints. For neurosteroid mechanism work, more selective compounds exist. DHEA occupies an uncomfortable middle ground: too mainstream and over-investigated to feel like frontier research, not specific enough mechanistically to serve as a clean probe tool.

We think the honest framing is that DHEA was a rational priority in the 1990s and 2000s, serious investigators did that work carefully, and the signal that emerged is real but modest and largely population-specific. As a reference standard for endogenous steroid panels or as a benchmark in age-related endocrine decline studies, it still earns a place in the lab. As a primary research question in 2025, the room is very crowded and the probability of a surprising new finding is low.

Novelty

18

Mechanism promise

38

In-category differentiation

25

Evidence quality

50

Translational signal

38

Research bench value

35

Rationale DHEA has a large, serious clinical literature but three decades of investigation have produced consistently modest and population-specific effects; novelty is minimal and differentiation is weak because more selective tools exist for each of its proposed mechanisms. Scored as established-mature, analogous to piracetam on the maturity axis.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous androgen precursor

An endogenous adrenal steroid hormone with androgenic and neurosteroid activity; declines with age and supplemented for hormone restoration.

Abstract

DHEA (dehydroepiandrosterone; CAS 53-43-0; molecular formula C19H28O2; molecular weight 288.42) is an endogenous adrenal steroid hormone produced by the adrenal cortex. DHEA and its sulfate (DHEAS) are the most abundant circulating steroid hormones in young adults; both decline progressively with age, reaching 10 to 20 percent of peak by age 70. The compound is a precursor for downstream androgen and estrogen synthesis and is also a sigma-1 receptor ligand and NMDA receptor PAM with neurosteroid activity. Supplementation has been studied for adrenal insufficiency, depression in older adults, sexual dysfunction, and cognitive function with mixed results. The compound is sold as a dietary supplement in the United States but is prescription-only or banned in many other jurisdictions. Doses are typically 25 to 100 mg per day; female subjects often require lower doses to avoid virilizing effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-160Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Ginkgo Biloba

Plain-language summaryIntrigue 52 / 100

Ginkgo biloba is a maidenhair tree leaf extract widely used for cerebral circulation and cognitive function. The ginkgolides and bilobalides are the principal active compounds. Used historically for stroke and dementia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

26/100

Overhyped cognitive herb whose flagship dementia indication failed large RCTs; narrow PAF antagonist probe value remains

Look, ginkgo biloba is one of the most studied herbals on the planet, and that’s actually part of the problem. When you have thirty years of serious clinical work on a compound and the headline result is two large negative trials, you dont have a promising research target. You have a cautionary tale about wishful mechanism extrapolation.

The chemistry is genuinely interesting at the level of pharmacognosy. EGb 761, the standardized European extract, delivers roughly 24 percent flavonoid glycosides and 6 percent terpene lactones, with ginkgolides A, B, and C plus bilobalide carrying most of the pharmacological weight. Ginkgolide B is a real platelet-activating factor antagonist, and thats the mechanism that generated the most optimism for decades. Add modest MAO inhibition and broad antioxidant activity, and you have a plausible story for cerebrovascular and cognitive effects. On paper.

The problem is that on paper is where the dementia story largely stayed. The GEM trial (DeKosky et al., JAMA 2008) randomized over 3,000 community-dwelling older adults and found no reduction in dementia incidence versus placebo. GuidAge (Vellas et al., Lancet Neurology 2012) ran for five years in a high-risk population of older adults with spontaneous memory complaints and found the same: no effect on conversion to Alzheimer’s. Two large, multi-site, well-funded randomized trials. Both negative on primary endpoints. The evidence quality is high in the sense that the trials were methodologically competent; the translational signal is poor in the sense that the compound didn’t move what mattered.

There’s a more defensible case for peripheral arterial disease. Cochrane meta-analyses on intermittent claudication find a modest walking-distance benefit, which tracks more cleanly with the PAF antagonism story than the cognitive angle ever did. But modest improvement in claudication walking distance is not a frontier research question in 2026.

We don’t see a compelling case for featuring ginkgo prominently in an active research program. Ginkgolide B retains some use as a reference PAF antagonist if your question is specifically about platelet-activating factor biology, but cleaner, more selective PAF antagonists exist for that purpose. Everything else about ginkgo is either exhaustively characterized or definitively addressed by trials that came back empty. The compound earns its place in pharmacognosy textbooks. It doesn’t earn a high spot in a library built around compounds where the frontier is still genuinely open.

Novelty

15

Mechanism promise

20

In-category differentiation

15

Evidence quality

60

Translational signal

28

Research bench value

25

Rationale Ginkgo’s PAF antagonism and antioxidant chemistry are real but decades-old, and the GEM and GuidAge trials decisively closed the dementia prevention question; the common OTC herb cap of 35 would apply categorically but the raw calculation lands at 26, making it moot.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Maidenhair tree leaf extract

Standardized extract of Ginkgo biloba leaves used for cognitive function and peripheral circulation, characterized by flavonoid glycosides and terpene lactones.

Abstract

Ginkgo biloba is the world’s oldest living tree species, with leaves used in traditional Chinese medicine and standardized extracts (EGb 761) marketed in Europe for cognitive impairment and peripheral arterial disease. Active constituents are flavonoid glycosides (24 percent in EGb 761) and terpene lactones (ginkgolides A, B, C; bilobalide; 6 percent). Pharmacology includes platelet activating factor (PAF) antagonism (ginkgolides), MAO inhibition (modest), and antioxidant activity. The clinical evidence base in dementia is mixed (large GEM and GuidAge trials negative); peripheral arterial disease evidence is more positive. Doses are typically 120 to 240 mg of standardized extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-176Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Milnacipran

Plain-language summaryIntrigue 60 / 100

Milnacipran, sold as Savella in the US (Ixel in Europe), is an SNRI primarily used for fibromyalgia. The European indication is depression. The (1S,2R)-enantiomer (levomilnacipran, Fetzima) is sold separately as a depression-focused agent. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Approved SNRI with balanced SERT/NET profile, largely superseded by levomilnacipran for bench research

Milnacipran is a second-generation SNRI that has been on the market in France since 1997 and hit the US in 2009 as Savella, specifically for fibromyalgia. It operates the same fundamental way as venlafaxine and duloxetine – blocking serotonin and norepinephrine reuptake – but with a meaningfully different ratio. Most SNRIs are heavily SERT-biased; milnacipran sits at roughly 1:1 SERT/NET at therapeutic doses and tips toward NET preference at lower doses. Thats the whole pharmacological story here, and it’s a real if modest differentiator from the rest of its class.

Here’s the thing: that balanced profile was genuinely interesting when milnacipran first emerged, because the hypothesis that NET-biased SNRIs might address pain states differently than serotonin-dominant ones had real scientific logic. The fibromyalgia approval is direct evidence this logic played out, at least partially – FDA reviewers saw enough signal in the phase 3 data to greenlight it. The evidence base is solid. Multiple RCTs, decent N, regulatory approval in multiple jurisdictions. These aren’t things you dismiss.

What we don’t love is where milnacipran sits in the landscape right now. Levomilnacipran (Fetzima), the active (1S,2R) enantiomer, arrived in 2013 with even greater NET selectivity and largely superseded milnacipran as the compound of interest for investigators who care about the norepinephrine angle. If youre running a mechanistic study on NET inhibition ratios, you’re probably reaching for levomilnacipran or reboxetine before milnacipran. The parent compound doesn’t have a compelling edge over its own metabolite derivative, and that’s a real problem for differentiation scoring.

The fibromyalgia indication is the most distinctive thing about milnacipran from a research standpoint, and the central pain sensitization story is genuinely interesting biology. But the compound’s role there is more about demonstrating that central sensitization can be modulated pharmacologically than about milnacipran specifically being irreplaceable. Duloxetine covers overlapping ground with a larger evidence base and broader indication set. If your program is in central sensitization or fibromyalgia pathophysiology, milnacipran is a useful historical reference point but probably not your primary tool.

We see milnacipran as a mature approved pharmaceutical with well-characterized PK, a real if narrow clinical role, and limited headroom for novel research programs. It’s not junk – the fibromyalgia signal is real and the balanced monoamine profile remains a valid study tool for comparing SERT vs NET contributions across contexts. But for most bench programs in 2025, milnacipran has been superseded either by levomilnacipran for NET questions or duloxetine for fibromyalgia translational work with a larger literature behind it. The score reflects an approved, evidence-backed compound that has largely served its primary research purpose.

Novelty

22

Mechanism promise

38

In-category differentiation

28

Evidence quality

72

Translational signal

68

Research bench value

35

Rationale Milnacipran is a mature approved SNRI with genuine clinical utility in fibromyalgia, but its balanced SERT/NET profile is no longer novel and the active enantiomer levomilnacipran has largely superseded it for mechanistic research; evidence quality is high but novelty and differentiation are low, pulling the overall into the low-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin-norepinephrine reuptake inhibitor

An SNRI marketed in Europe and Japan for depression and FDA-approved for fibromyalgia, with balanced SERT/NET inhibition.

Abstract

Milnacipran (Savella, Ixel; CAS 92623-85-3; molecular formula C15H22N2O; molecular weight 246.35) is a serotonin-norepinephrine reuptake inhibitor (SNRI) marketed in Europe, Japan, and Australia for major depressive disorder and FDA-approved in 2009 (Savella) for fibromyalgia. The compound has more balanced SERT and NET inhibition than venlafaxine or duloxetine (which are SERT-biased), with NET inhibition more prominent at lower doses. Approved doses are 100 mg per day in two divided administrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-192Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Duloxetine

Plain-language summaryIntrigue 71 / 100

Duloxetine (Cymbalta) is an SNRI from Eli Lilly, approved in 2004, that hits the serotonin and norepinephrine pumps in roughly balanced fashion across its dose range (unlike venlafaxine, which only becomes a true SNRI at higher doses). The norepinephrine half of the action turns out to be useful for chronic pain, because pain-modulating circuits in the spinal cord rely on norepinephrine signaling. That is why duloxetine carries FDA approvals not just for depression and generalized anxiety but also for diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain, an unusually broad label for an antidepressant. Liver enzyme effects are notable, particularly through CYP1A2 and CYP2D6. Discontinuation is rough but generally less severe than venlafaxine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature approved SNRI with genuine pain indications but no meaningful research frontier left to explore

Look, duloxetine is a good drug. It does what it says. The dual SERT/NET inhibition is clean, the SERT/NET ratio of roughly 10 is genuinely more balanced than venlafaxine’s 30, and the regulatory approval across five distinct indications, including fibromyalgia and diabetic peripheral neuropathic pain, reflects a real pharmacological story about noradrenergic tone in descending pain modulation. We’re not dismissing it. We’re just being honest that 2004 was a long time ago and the mechanism has been worked to death.

The norepinephrine angle on pain is the most interesting thing here, and it remains the reason investigators reach for duloxetine as a reference compound when studying spinal descending inhibition. If you’re building a model of central sensitization or dorsal horn noradrenergic modulation, duloxetine is the logical positive control. Thats the bench value we credit, and it’s real. But it’s reference-standard bench value, not frontier probe value. You’re using it to anchor a system, not to ask a new question.

On the mechanism front, SNRI pharmacology is about as well-characterized as anything in psychopharmacology. CYP1A2 as primary metabolizer, moderate CYP2D6 inhibition producing real interactions with TCAs and tamoxifen, half-life around 12 hours. All of this is in every pharmacology textbook. We’re not finding anything new here. The dual-target story was genuinely exciting when Lilly was pushing it through FDA, but single receptor plus single receptor is not what we mean by multi-target pharmacology in 2026. Compare it to something like the dual GIP/GLP-1 biology in tirzepatide and you see how far the field has moved on what counts as interesting dual-target action.

The differentiation story is the strongest case for scoring this higher than a generic SSRI. Duloxetine occupies a real niche: it’s the approved-for-pain SNRI with the most balanced affinity profile, which gives it a genuine foothold in musculoskeletal and neuropathic pain research that compounds like escitalopram simply don’t have. It’s not one of many identical entries in its actual category, the pain-plus-mood space is thinner than it looks. But that unique angle doesn’t translate to research excitement because the mechanism explaining that unique angle is fully understood and the clinical effect is well-characterized.

Honestly, if you’re studying chronic pain biology, duloxetine earns a spot in your lab as a comparator. If you’re looking for the next thing in mood pharmacology or central sensitization, there is no reason to center a research program on it. The score reflects that. High evidence, high translation, low novelty, low mechanism excitement. That math produces a middle score, and a middle score is exactly right.

Novelty

18

Mechanism promise

28

In-category differentiation

42

Evidence quality

82

Translational signal

78

Research bench value

55

Rationale Duloxetine’s evidence quality and translational signal are genuinely high (it’s a multi-indication approved drug with solid phase 3 data), but those axes are the least-weighted in this rubric precisely because compelling evidence on a boring question isn’t what the library is for. Novelty is low, mechanism is well-trodden SNRI pharmacology, and the primary research value is as a reference standard for descending pain modulation work rather than as a frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Serotonin-norepinephrine reuptake inhibitor

A balanced-affinity SNRI distinguished by approval for chronic pain and diabetic peripheral neuropathy in addition to depression.

Abstract

Duloxetine ((S)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine; CAS 116539-59-4; molecular formula C18H19NOS; molecular weight 297.41) is a balanced-affinity SNRI developed at Eli Lilly and approved by the FDA in 2004 under the trade name Cymbalta. SERT (Ki approximately 0.8 nM) and NET (Ki approximately 7.5 nM) affinities are both nanomolar, with a SERT/NET ratio of roughly 10, more balanced than venlafaxine (ratio approximately 30). The compound exhibits weak DAT inhibition (Ki approximately 240 nM) of marginal clinical relevance. Plasma half-life is approximately 12 hours; metabolism is via CYP1A2 (primary) and CYP2D6 (secondary). The compound is itself a moderate CYP2D6 inhibitor, producing relevant interactions with TCAs, antipsychotics, and tamoxifen. Approved indications include major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain. The pain indications reflect the noradrenergic component’s role in descending pain modulation. Used as the canonical balanced SNRI in mechanism studies and as a reference compound for descending pain modulation research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-209Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Selegiline

Plain-language summaryIntrigue 70 / 100

Selegiline is a Hungarian discovery by Joseph Knoll from the 1960s that selectively and irreversibly knocks out MAO-B, an enzyme that breaks down dopamine in the brain. At low oral doses (5 to 10 mg) it is used to slow Parkinson disease progression; at higher doses it loses its selectivity and starts inhibiting MAO-A as well, which produces antidepressant effects but reintroduces the dietary tyramine restrictions that make MAOIs cumbersome. A skin patch formulation (Emsam) bypasses the gut MAO-A, allowing depression-strength dosing without the cheese-effect risk. The body breaks selegiline down into amphetamine and methamphetamine as metabolites, which contribute to its stimulant feel and complicate its use in patients screened for substance use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

43/100

Mature MAO-B reference tool largely superseded by rasagiline for new bench programs

Look, selegiline has been around since Joseph Knoll’s group in Hungary in the 1960s, and the literature around it is enormous. DATATOP enrolled over 800 patients and remains one of the cleaner neuroprotection trials in movement disorders, even if the disease-modification question never fully resolved. The FDA approval for Parkinson disease (oral) and for depression via the Emsam transdermal patch is genuine clinical validation. We dont dismiss that.

But when you’re evaluating selegiline as a research target today, you’re working with a compound that has almost no uncharted surface area in its primary mechanism. Irreversible MAO-B inhibition via the propargyl moiety is understood at the crystallographic level. The selectivity window (approximately 100:1 MAO-B over MAO-A at low oral doses, collapsing above 20 mg daily) has been characterized exhaustively. The tyramine interaction is fully mapped. The amphetamine and methamphetamine metabolites are the well-known complication. Thats the whole compound, mechanistically speaking.

The more interesting angle is the neuroprotection hypothesis that runs independent of MAO inhibition. The propargylamine pharmacophore activates anti-apoptotic pathways (Bcl-2 upregulation, GAPDH nuclear translocation blockade) in a way that appears enzyme-independent. Selegiline and rasagiline both show this in vitro. Here’s the problem: rasagiline is now the preferred probe for that biology. Cleaner metabolite profile, no amphetamine byproducts, more potent MAO-B IC50. If youre investigating propargylamine neuroprotection, youre probably reaching for rasagiline, not selegiline.

The Emsam story does deserve credit. Bypassing first-pass GI MAO-A inhibition to achieve antidepressant plasma levels without tyramine restriction at the low-dose patch is genuinely clever delivery pharmacology. The FDA approved it in 2006 and theres real efficacy data behind it. But the depression mechanism itself isnt a frontier question; MAOI pharmacology is mature, and the clinical outcomes from Emsam are established. There isnt much new to discover there.

We think selegiline belongs in a well-stocked reference library as exactly what it is: the original selective MAO-B inhibitor, a critical historical reference compound, and occasionally the right tool when matched comparators to early Parkinson trial design matter. For new research programs asking novel questions in dopaminergic biology, MAO-B selectivity, or propargylamine neuroprotection, rasagiline now sets the standard. Selegiline earns its place, but it’s not where the interesting questions are being answered right now.

Novelty

18

Mechanism promise

38

In-category differentiation

28

Evidence quality

72

Translational signal

68

Research bench value

52

Rationale Selegiline is a 1960s compound with FDA approval in two indications and an enormous clinical literature; its mechanism is resolved at the crystallographic level, its metabolite liabilities are fully characterized, and rasagiline now dominates the propargylamine MAO-B niche with cleaner pharmacology. Evidence quality and translational signal are high because it’s an approved drug, but novelty and differentiation pull the overall score firmly into established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective irreversible MAO-B inhibitor

A propargyl phenethylamine MAO-B inhibitor used in Parkinson disease and at higher doses in depression via MAO-A engagement.

Abstract

Selegiline ((R)-N-methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine; CAS 14611-51-9; molecular formula C13H17N; molecular weight 187.28) is an irreversible propargyl-substituted MAO-B inhibitor developed by Joseph Knoll in Hungary in the 1960s. At low oral doses (5 to 10 mg daily) the compound is selective for MAO-B (selectivity ratio approximately 100:1 over MAO-A), preventing dopamine catabolism in the basal ganglia and providing modest symptomatic benefit and possibly disease-modifying effect in Parkinson disease (DATATOP trial). At higher doses (above 20 mg daily) selectivity is lost and MAO-A inhibition contributes, producing classical MAOI antidepressant pharmacology with the corresponding tyramine cheese-effect risk. The transdermal patch (6 to 12 mg/24 h, Emsam) achieves antidepressant plasma levels while bypassing first-pass GI MAO-A inhibition, mitigating the tyramine restriction at the low-dose patch (6 mg). Metabolites include amphetamine and methamphetamine, contributing to subjective alertness and complicating drug screening. Used as a reference MAO-B selective inhibitor in Parkinson research and as a transdermal MAOI in depression studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-224Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Pimavanserin

Plain-language summaryIntrigue 72 / 100

Pimavanserin (Nuplazid) is the first FDA-approved drug for Parkinson disease psychosis, brought to market by ACADIA in 2016. It is also the first antipsychotic without any dopamine receptor activity at all, which makes it pharmacologically unique in its class. Mechanistically it is a selective 5-HT2A inverse agonist (it actively turns off the receptor’s baseline signaling rather than just blocking serotonin from binding). Because it leaves dopamine signaling alone, it does not worsen the motor symptoms of Parkinson disease the way standard antipsychotics do. The 2016 approval was politically contentious because mortality data in elderly trial patients was concerning, and a 2019 follow-up trial in dementia-related psychosis failed. Still in clinical use specifically for Parkinson psychosis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

64/100

The reference selective 5-HT2A inverse agonist; approved, well-evidenced, and a genuine research probe but no longer novel

Look, pimavanserin occupies a strange position in the research library. It’s an approved drug, which means the clinical evidence story is unusually clean for something you’d find in a peptide-adjacent catalog, and the mechanism is as elegant as anything in CNS pharmacology. But elegant and nine-years-old are two different things, and the novelty axis is where this compound gives ground.

The core story: ACADIA built a compound with essentially perfect selectivity for 5-HT2A (Ki ~0.087 nM) over everything else, and importantly over dopamine receptors entirely. D2 affinity above 1000 nM means it has no meaningful dopaminergic activity, which is the whole clinical insight. Parkinson disease psychosis is a therapeutic dead zone because every conventional antipsychotic that quiets hallucinations through D2 blockade will simultaneously aggravate motor symptoms. Pimavanserin sidesteps that entirely. Thats not a small pharmacological trick; it’s a genuinely useful dissection of what 5-HT2A signaling contributes versus what D2 blockade contributes in the psychotic state.

The inverse agonist distinction matters for bench work. Pimavanserin doesn’t just block 5-HT2A signaling, it reduces constitutive activity below baseline. If you’re asking what tonic 5-HT2A receptor activity does in a given circuit, simple antagonism can’t answer that cleanly. Pimavanserin can. We think that probe value is real and underappreciated in groups working on cortical 5-HT2A biology, psychedelic pharmacology (where 5-HT2A agonism is the mechanism of interest), and antipsychotic drug discovery.

Evidence is solid in the approved indication. Multiple phase 3 RCTs in PD psychosis, FDA approval in 2016, and a mature pharmacokinetic profile that investigators can work with (57-hour parent t1/2, 200-hour active metabolite, CYP3A4-driven metabolism). The supplemental NDA for Alzheimer’s disease psychosis was a setback: FDA rejected it in 2022 despite the HARMONY trial data, citing insufficient evidence of effect and the class black-box mortality signal. The MDD augmentation program is still live and there’s genuine mechanistic rationale there, but that pipeline is not yet definitive.

What we like: the selectivity profile is irreplaceable if you’re doing 5-HT2A receptor biology and need to avoid dopaminergic confounds. What we don’t like: the novelty window is mostly closed. The literature is deep enough that incremental new findings aren’t the frontier anymore. The Alzheimer’s program being paused removes the most compelling near-term indication expansion. For groups actively studying 5-HT2A function, psychedelic neuroscience, or antipsychotic mechanism, pimavanserin stays relevant as the reference tool. For everyone else, the 64 reflects that this is a well-understood, well-evidenced compound doing exactly what it was designed to do, with no serious surprises left in the mechanism.

Novelty

40

Mechanism promise

63

In-category differentiation

72

Evidence quality

72

Translational signal

72

Research bench value

72

Rationale Pimavanserin scores well on differentiation and bench value because it is the canonical selective 5-HT2A inverse agonist probe with no dopaminergic liability, making it irreplaceable for dissecting constitutive 5-HT2A signaling. Novelty pulls the composite down hard: FDA approval was 2016, mechanism is fully characterized, and the high-profile Alzheimer’s disease psychosis program was rejected by FDA in 2022, so the indication expansion story is cooler than the outcome.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective 5-HT2A inverse agonist

The first FDA-approved drug for Parkinson disease psychosis; a selective 5-HT2A inverse agonist with no dopamine receptor activity.

Abstract

Pimavanserin (1-[(4-fluorophenyl)methyl]-1-[(1-methyl-4-piperidinyl)methyl]-3-{4-[(2-methylpropoxy)]phenyl}urea; CAS 706779-91-1; molecular formula C25H34FN3O2; molecular weight 427.56) is a selective 5-HT2A inverse agonist developed at ACADIA and approved by the FDA in 2016 under the trade name Nuplazid. Distinct among antipsychotics by absence of dopamine receptor activity: D2 affinity is greater than 1000 nM, with no clinically relevant binding. Selectivity is for 5-HT2A (Ki approximately 0.087 nM) over 5-HT2C (Ki approximately 0.4 nM, approximately 5-fold selective). The compound is a high-efficacy inverse agonist (not merely an antagonist), reducing constitutive 5-HT2A signaling below baseline. The dopaminergically clean profile is uniquely suited to Parkinson disease psychosis, where conventional antipsychotics’ D2 antagonism worsens motor symptoms; pimavanserin treats hallucinations and delusions without aggravating bradykinesia or rigidity. Plasma half-life is 57 hours for parent compound, 200 hours for active metabolite. Metabolism is via CYP3A4 and CYP3A5. The compound carries an FDA black-box warning for increased mortality in elderly dementia patients (a class warning for all antipsychotics). Used as the reference selective 5-HT2A inverse agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-240Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Propranolol

Plain-language summaryIntrigue 73 / 100

Propranolol (Inderal) is the first commercially successful beta-blocker, developed by James Black at ICI and approved by the FDA in 1967. Black’s work on it earned him the Nobel Prize and reshaped cardiovascular medicine. It blocks both subtypes of beta-adrenergic receptor, dampening the heart’s response to adrenaline as well as the bronchial and metabolic effects. Beyond its many cardiovascular uses, it has a substantial second life in psychiatry and neurology: it is the standard prescription for performance anxiety (one or two tablets before public speaking blunts the heart-pounding and tremor without affecting cognition), is first-line for migraine prevention, and has been studied for trauma memory reconsolidation in PTSD. Lipophilic enough to cross into the brain, which contributes to both its therapeutic and side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Historical cornerstone with almost no remaining research novelty; valuable as a canonical non-selective beta-blocker probe

Look, propranolol is one of the most consequential drugs in the history of pharmacology. James Black’s Nobel Prize was built partly on it. And yet, as a research target in 2026, it’s almost entirely spent. That’s the tension the score reflects, and it’s not a close call.

The cardiovascular evidence base is airtight. Hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor — six approved indications and decades of replicated RCTs sitting behind each of them. The pharmacokinetics have been characterized exhaustively: non-selective beta-1 and beta-2 blockade, 3-to-6 hour half-life, high lipophilicity giving CNS penetration that hydrophilic competitors like atenolol and nadolol simply lack. Those properties earned it permanent status as the reference non-selective beta-blocker. That reference-compound identity is essentially its only remaining research value — real, but narrow.

The most interesting live research angle is the PTSD memory reconsolidation work, and we want to be honest about what that actually is. The mechanistic logic is genuinely clever: noradrenergic signaling in the basolateral amygdala is required for fear memory reconsolidation, so blocking beta-adrenergic receptors during a deliberate recall event should attenuate reconsolidation and weaken the traumatic memory. Pitman’s Harvard MGH group published the original proof-of-concept in 2002. Alain Brunet’s Montreal lab has been the most persistent investigator, including a 2018 randomized trial in PTSD patients showing meaningful symptom reduction. The signal is real. But the 2019 Cochrane review found the evidence base insufficient, effect sizes across studies are modest, and its been 24 years since the founding paper. Calling this novel would be a stretch.

The novelty problem is fundamental. Beta-adrenergic blockade has been understood mechanistically since the 1960s. No new chemistry, no new mechanisms, no structural innovations. For reconsolidation paradigms specifically, metoprolol covers most of the same ground, and timolol is another option with similar CNS access. Propranolol has first-mover advantage in this niche and a denser associated literature, but its not uniquely irreplaceable in most bench designs.

What we like: the translational track record is definitive, and for performance anxiety studies, adrenergic probe work, or reconsolidation paradigms, its the right tool and the right reference. What we don’t like: the mechanism is fully characterized, the novelty is gone, and the questions propranolol can uniquely answer are getting fewer every year. A serious investigator building a new research program around propranolol in 2026 would need a very specific reason. This is a historical cornerstone, not a frontier compound.

Novelty

10

Mechanism promise

20

In-category differentiation

30

Evidence quality

80

Translational signal

80

Research bench value

50

Rationale Propranolol scores extremely low on novelty and mechanism — it’s a 1967 drug with single-receptor, fully-characterized pharmacology and no new chemistry — but pulls evidence and translational scores high owing to its approved-drug status across six indications and 60 years of clinical use; the PTSD memory reconsolidation angle is the most interesting current research use case, but Pitman’s foundational work is 24 years old and replication remains mixed, preventing a meaningful novelty rescue.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-selective beta-adrenergic antagonist

A non-selective beta-adrenergic antagonist; the first beta-blocker, repurposed for performance anxiety and migraine prophylaxis.

Abstract

Propranolol (1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 525-66-6; molecular formula C16H21NO2; molecular weight 259.34) is a non-selective beta-adrenergic antagonist developed by James Black at ICI and approved by the FDA in 1967 under the trade name Inderal. The compound is the first commercially successful beta-blocker, foundational to modern cardiovascular pharmacology. Beta-1 affinity is approximately equal to beta-2 affinity (non-selective). Plasma half-life is 3 to 6 hours; the lipophilic structure produces high CNS penetration, distinguishing propranolol from hydrophilic beta-blockers (atenolol, nadolol) for indications requiring central effect. Approved indications include hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor, and hypertrophic cardiomyopathy. Off-label use is extensive: performance anxiety (most common psychiatric indication), PTSD memory reconsolidation, akathisia, hyperthyroid tachycardia. The 5-HT receptor partial agonism (weak) was a former curiosity but is not clinically meaningful at standard doses. Used as the canonical non-selective beta-blocker reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-256Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Raloxifene

Plain-language summaryIntrigue 60 / 100

Raloxifene (Evista) is a second-generation SERM approved in 1997 for postmenopausal osteoporosis, with a secondary indication for breast cancer prevention in high-risk women. Where tamoxifen is a partial activator in the uterus (creating an endometrial cancer risk), raloxifene is a blocker there as well as in the breast, eliminating that risk. It still acts as a partial activator in bone and liver, supporting the bone density and lipid-profile improvements. Trade-offs: more hot flashes than tamoxifen and increased risk of blood clots. The MORE and STAR trials established its osteoporosis and breast-cancer-prevention efficacy, respectively. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Second-generation SERM (benzothiophene)

A benzothiophene SERM; an osteoporosis drug with breast cancer prevention activity but no uterine partial agonism, distinguishing it from tamoxifen.

Abstract

Raloxifene ([6-hydroxy-2-(4-hydroxyphenyl)benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone; CAS 84449-90-1; molecular formula C28H27NO4S; molecular weight 473.58) is a benzothiophene second-generation SERM developed at Eli Lilly and approved by the FDA in 1997 under the trade name Evista. Distinct from tamoxifen by tissue selectivity profile: ER antagonism in breast and uterus, partial agonism in bone and liver. The absence of uterine partial agonism eliminates the endometrial cancer risk seen with tamoxifen and is the principal distinguishing clinical feature. Plasma half-life is approximately 27 hours; metabolism is via glucuronidation. Approved for postmenopausal osteoporosis treatment and prevention, and for breast cancer risk reduction in postmenopausal women at high risk. The MORE and STAR trials established the breast cancer prevention activity. Adverse events include thromboembolism (similar to tamoxifen), hot flashes, and leg cramps. Used as the canonical second-generation SERM with bone-selective profile.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-272Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 58 59 60 61 62 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.